Navigation Links
Delcath Receives Notice of European Regulatory Approval for Hepatic CHEMOSAT™ Delivery System
Date:4/13/2011

rgans or regions of the body, while controlling the systemic exposure of those agents. The Company's initial focus is on the treatment of primary and metastatic liver cancers. In 2010, Delcath concluded a Phase III metastatic melanoma study, and the Company recently completed a multi–arm Phase II trial to treat other liver cancers. The Company has not yet received FDA approval for commercial sale of its system. For more information, please visit the Company's website at www.delcath.com.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward–looking statements made by the Company or on its behalf. This news release contains forward–looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to the time required to build inventory and establish commercial operations in Europe, adoption, use and resulting sales for the Hepatic CHEMOSAT delivery system in the EEA, if any, our ability to successfully commercialize the chemosaturation system and the potential of the chemosaturation system as a treatment for patients with terminal metastatic disease in the liver, acceptability of the Phase III clinical trial data by the FDA, our ability to address the issues raised in the Refusal to File letter received from the FDA and the timing of our re-submission of our NDA, re-submission and acceptance of the Company's NDA by the FDA, approval of the Company's NDA for the treatment of metastatic melanoma to the liver, adoption, use and resulting sales in the United States, if any, approval of the current or future chemosaturation system for other indications, actions by the FDA or other foreign regulatory agencies, our ability to successfully enter into distribution and strategic partnership agree
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Delcath to Update Investors on FDA Meeting
2. Delcath Expands Board of Directors With Appointment of Gabriel Leung
3. Delcath to Present at Upcoming Investor Conferences
4. Delcath Systems Receives Refusal to File Letter From FDA
5. Delcath Achieves ISO 13485 Certification
6. Delcath Completes New Drug Application Submission to the FDA for the Chemosaturation Delivery System
7. Delcath Systems Announces Third Quarter Progress Report Conference Call
8. Delcath Strengthens Research and Development Team with Key Appointments
9. Delcath Signs Agreement With Synerx and Mylans Bioniche Teoranta for Melphalan Supply
10. Delcath to Present at the William Blair Emerging Growth Stock Conference
11. Delcath to Present at the JMP Securities Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... DUBLIN , Aug. 29, 2014 ... the "Global Multiple Sclerosis Drugs Market 2014-2018" ... is a chronic, inflammatory medical condition that results in ... damaged because of an abnormal response by the immune ... (CNS). It is a potentially debilitating disease in which ...
(Date:8/29/2014)... 29, 2014  Abaxis, Inc. (NasdaqGS: ABAX ... and consumables to the medical, research and veterinary markets, ... Chief Executive Officer, will present at the CL King ... Tuesday, September 9, 2014 at 12:30 p.m. ET. The ... Hotel in New York City . ...
(Date:8/29/2014)... MENLO PARK, Calif. , Aug. 29, 2014 /PR ... ("DelMar" "the Company") today announced the filing of June ... changed its fiscal year end to June 30th in ... stock on a national securities exchange in the timeliest ... with the United States Securities Exchange Commission can be ...
Breaking Medicine Technology:Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3Abaxis, Inc. to Present at CL King's 12th Annual Best Ideas Conference 2014 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 5
... NEW YORK, Sept. 6, 2011 ... research report is available in its ... Contract Research Organizations (CRO) - Asia-Pacific, ... Benefit from Rising Financial and Regulatory ...
... BLUE BELL, Pa., Sept. 6, 2011 Inovio Pharmaceuticals, ... in the development of therapeutic and preventive vaccines against ... board with the appointment of two prominent leaders in ... advisory board are Dr. Thomas S. Edgington, Emeritus Professor ...
Cached Medicine Technology:Top 20 Contract Research Organizations (CRO) - Asia-Pacific, Especially India and China, Positioned to Benefit from Rising Financial and Regulatory Pressures in Western Pharmaceutical Markets 2Top 20 Contract Research Organizations (CRO) - Asia-Pacific, Especially India and China, Positioned to Benefit from Rising Financial and Regulatory Pressures in Western Pharmaceutical Markets 3Top 20 Contract Research Organizations (CRO) - Asia-Pacific, Especially India and China, Positioned to Benefit from Rising Financial and Regulatory Pressures in Western Pharmaceutical Markets 4Top 20 Contract Research Organizations (CRO) - Asia-Pacific, Especially India and China, Positioned to Benefit from Rising Financial and Regulatory Pressures in Western Pharmaceutical Markets 5Top 20 Contract Research Organizations (CRO) - Asia-Pacific, Especially India and China, Positioned to Benefit from Rising Financial and Regulatory Pressures in Western Pharmaceutical Markets 6Top 20 Contract Research Organizations (CRO) - Asia-Pacific, Especially India and China, Positioned to Benefit from Rising Financial and Regulatory Pressures in Western Pharmaceutical Markets 7Top 20 Contract Research Organizations (CRO) - Asia-Pacific, Especially India and China, Positioned to Benefit from Rising Financial and Regulatory Pressures in Western Pharmaceutical Markets 8Top 20 Contract Research Organizations (CRO) - Asia-Pacific, Especially India and China, Positioned to Benefit from Rising Financial and Regulatory Pressures in Western Pharmaceutical Markets 9Top 20 Contract Research Organizations (CRO) - Asia-Pacific, Especially India and China, Positioned to Benefit from Rising Financial and Regulatory Pressures in Western Pharmaceutical Markets 10Inovio Pharmaceuticals Adds Two Medical Innovators to Its Scientific Advisory Board 2Inovio Pharmaceuticals Adds Two Medical Innovators to Its Scientific Advisory Board 3Inovio Pharmaceuticals Adds Two Medical Innovators to Its Scientific Advisory Board 4Inovio Pharmaceuticals Adds Two Medical Innovators to Its Scientific Advisory Board 5
(Date:8/30/2014)... Colorado (PRWEB) August 30, 2014 Daily Gossip ... called the Make Him Desire You program, who shows a ... , The author of this method says that the program ... , The Make Him Desire You review indicates that the ... amazing insider advice and his great techniques to make a ...
(Date:8/30/2014)... 2014 Daily Gossip reveals in its recently ... a method created by Sarah Summer, who can perfectly understand ... of this new program actually had to deal with this ... be able to access it, in an all-natural holistic cure ... finding an effective cure for yeast infection. The author of ...
(Date:8/30/2014)... New York (PRWEB) August 30, 2014 ... combination of Nutrition and Pharameuticals. Nutraceuticals is a ... extracting healthy ingredients from natural food sources. Nutraceutical ... health benefits to the human body. Nutraceutical health ... diet supplements, fortified foods and more. Although nature ...
(Date:8/30/2014)... August 30, 2014 Ticket Down ... Open Tennis Championship tickets in NYC. This ... code US-OPEN-2014 for all day session, evening session, courtside ... sales for this prestigious Grand Slam Tournament. , The ... 8/30/14 , US Open Tennis Championship: Men's/Women's 3rd Round ...
(Date:8/30/2014)... After offering hyperbaric oxygen therapy ... past several years, Dr. Roy Schmidt and the ... a scholarship program for veterans who have been ... held this summer to discuss veterans’ needs ( ... shed light on the large number of veterans ...
Breaking Medicine News(10 mins):Health News:Make Him Desire You Review Reveals Powerful Formula to Make a Man Emotionally Addicted 2Health News:Natural Cure for Yeast Infection Review Exposes New Natural Treatment 2Health News:A Granular Analysis of the Nutraceutical Ingredients Market by Transparency Market Research 2Health News:A Granular Analysis of the Nutraceutical Ingredients Market by Transparency Market Research 3Health News:A Granular Analysis of the Nutraceutical Ingredients Market by Transparency Market Research 4Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 2Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 3Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 4Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 5Health News:Tennessee Hyperbaric Center Offering HBOT Scholarships to Veterans 2
... Ophthalmology hosts event October 24 benefiting,Juvenile Diabetes Research ... Oct. 17 Oklahoma Academy of,Ophthalmology (OAO) hosts ... Research Foundation (JDRF) Central Oklahoma Chapter., Actor, ... the,event. Lorena and Gary Story of Oklahoma City ...
... (Caltech) have created a "plug-and-play" synthetic RNA device--a sort ... in and responding to more than one biological or ... such devices could have a multitude of potential medical ... tumor cells or determine when to turn modified genes ...
... Behind New Resource, KUMASI, Ghana, Oct. 17 ... new hopeXchange Medical Center, a high quality,diagnostic and ... the ceremony, President Kufuor welcomed a high-profile mission,delegation ... the Cure(R),s President,and CEO Hala Moddelmog, and acknowledged ...
... MINNETONKA, Minn., Oct. 17 Cancer and its ... amounts of calories,protein and nutrients they need to help ... lose significant amounts of lean,muscle mass and weight because ... strong aversion to foods. These symptoms can lead to ...
... Mich., Oct. 17 Chrysler LLC and Henry,Ford ... bring an,innovative diabetes program to its Sterling Stamping ... the Henry Ford Health System,and is intended to ... existing workplace wellness initiatives. All employees at the,site ...
... Satyam Computer,Services Ltd. (NYSE: SAY ), a ... reported US GAAP results for its second,quarter, which ... Despite a challenging market that impacted several key ... exceeded its guidance in,the second quarter. Revenue was ...
Cached Medicine News:Health News:Second Annual 'Eye Ball' Fights Juvenile Diabetes, Says Oklahoma Academy of Ophthalmology 2Health News:Second Annual 'Eye Ball' Fights Juvenile Diabetes, Says Oklahoma Academy of Ophthalmology 3Health News:Caltech engineers build first-ever multi-input 'plug-and-play' synthetic RNA device 2Health News:New Specialty Hospital Dedicated in Ghana is Key Component of Susan G. Komen for the Cure(R)'s Debut in Africa 2Health News:New Specialty Hospital Dedicated in Ghana is Key Component of Susan G. Komen for the Cure(R)'s Debut in Africa 3Health News:New Specialty Hospital Dedicated in Ghana is Key Component of Susan G. Komen for the Cure(R)'s Debut in Africa 4Health News:Strong Bodies Battle Better 2Health News:Strong Bodies Battle Better 3Health News:Chrysler LLC Launches Workplace Diabetes Education Program 2Health News:Satyam Posts 28 Percent Year-over-Year Revenue Growth in Second Quarter Despite Slowdown in Key Markets 2Health News:Satyam Posts 28 Percent Year-over-Year Revenue Growth in Second Quarter Despite Slowdown in Key Markets 3Health News:Satyam Posts 28 Percent Year-over-Year Revenue Growth in Second Quarter Despite Slowdown in Key Markets 4Health News:Satyam Posts 28 Percent Year-over-Year Revenue Growth in Second Quarter Despite Slowdown in Key Markets 5Health News:Satyam Posts 28 Percent Year-over-Year Revenue Growth in Second Quarter Despite Slowdown in Key Markets 6Health News:Satyam Posts 28 Percent Year-over-Year Revenue Growth in Second Quarter Despite Slowdown in Key Markets 7Health News:Satyam Posts 28 Percent Year-over-Year Revenue Growth in Second Quarter Despite Slowdown in Key Markets 8Health News:Satyam Posts 28 Percent Year-over-Year Revenue Growth in Second Quarter Despite Slowdown in Key Markets 9Health News:Satyam Posts 28 Percent Year-over-Year Revenue Growth in Second Quarter Despite Slowdown in Key Markets 10
... to having been designed exclusively for vascular treatments, ... the Smartepil range which ensures fast amortisation of ... systems, it can be fitted with a polarised ... the target to be treated as well as ...
... SmartLite Derm is a KTP laser, ... of 532 nm (frequency doubled Nd:YAG) for ... by the comfortable color LCD Touch-screen. ... available are 0.3, 0.5, 0.7 and 1.0 ...
... a new and powerful instrument for ... system (MEL @308 nm - UVB) ... vitiligo. Designed to treat recalcitrant plaques, ... exposure of extensive lesions without irradiating ...
... a CO2 laser system with CW intensities ... dealing with all therapeutic application in modern ... medium-to-high intensities in super-pulsed mode, designed for ... It is also capable of supplying soft ...
Medicine Products: